South Korean medical aesthetics company Jeisys Medical (formerly Jetema) has secured approval for the Clinical Study Report (CSR) of its botulinum toxin type A product JTM201 in China, marking a critical step toward entering the world's largest aesthetic medicine market. The milestone signals a major supply-chain opportunity for overseas distributors and clinic buyers eyeing China's high-barrier toxin market, projected to reach 5 trillion won (approx. USD 3.7 billion) by 2030.
Trial results and regulatory progress
The Phase 3 trial enrolled 506 subjects and demonstrated non-inferiority to the original Botox in improving glabellar lines. At week 4, the investigator-assessed improvement rate reached 77.8%, and efficacy persisted in over 60% of patients at week 16. No neutralizing antibodies were detected during the study, suggesting low risk of resistance with repeated injections. Jeisys plans to submit a Biologics License Application (BLA) to Chinese authorities in the first half of 2025, targeting product launch in the second half of 2027.
Strategic partnership with Huadong Esthetics
Jeisys has already secured a 10-year, 550 billion won (approx. USD 410 million) long-term supply agreement with Huadong Esthetics, a leading Chinese aesthetic distribution company. This deal provides an estimated annual revenue base of 55 billion won post-approval. The partnership leverages Huadong's established distribution network, which already carries Jeisys' hyaluronic acid (HA) filler line Epitique, creating a synergistic portfolio for combination treatments.
Portfolio synergy and competitive edge
Jeisys' existing HA filler business in China provides a ready-made sales channel for the toxin product. The combination of fillers and toxins allows the company to target the growing combination procedure market, potentially boosting per-patient revenue. JTM201 is developed from an original European strain and has demonstrated long-lasting efficacy and safety data, positioning it well as the global toxin market shifts from price competition to quality and durability.
What buyers should watch
For overseas importers and clinic buyers, the key takeaway is the limited number of approved toxin products in China—a high-entry-barrier market. Jeisys' progress suggests a new, high-quality supply source may become available by late 2027. Distributors should monitor the BLA submission timeline and potential early access programs. The existing Huadong partnership also indicates a structured go-to-market strategy, reducing channel risk for downstream buyers.
Regulatory and channel signals
China's toxin market is tightly regulated, with only a few approved brands. Jeisys' successful Phase 3 results and CSR approval are strong indicators of regulatory readiness. The company's experience with HA filler registration in China further de-risks the approval pathway. Industry observers view this as a potential inflection point for Jeisys to evolve from a domestic Korean player into a global aesthetics contender.
Source: Read the original report | Published: June 02, 2026